Perrigo Company plc Business Acquisition, Pro Forma Net Income (Loss)
Perrigo Company plc (PRGO) reported Business Acquisition, Pro Forma Net Income (Loss) of -$9.60 million for the 12-month period ending 2022-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2025-02-28
- Perrigo Company plc business acquisition, pro forma net income (loss) for the quarter ending 2022-12-31 was $24.30M.
- Perrigo Company plc business acquisition, pro forma net income (loss) for the quarter ending 2022-10-01 was -$28.00M.
- Perrigo Company plc business acquisition, pro forma net income (loss) for the quarter ending 2022-07-02 was -$16.80M.
- Perrigo Company plc business acquisition, pro forma net income (loss) for the quarter ending 2022-04-02 was $10.80M.
- Perrigo Company plc business acquisition, pro forma net income (loss) for fiscal 2022 was -$9.60M.
- Perrigo Company plc business acquisition, pro forma net income (loss) for fiscal 2020 was -$148.60M, a 186.19% decline from fiscal 2019.
- Perrigo Company plc business acquisition, pro forma net income (loss) for fiscal 2019 was $172.40M, a 78.10% increase from fiscal 2018.
- Perrigo Company plc business acquisition, pro forma net income (loss) for fiscal 2018 was $96.80M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 3 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 12 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | $24.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$3.70M derived: sum of 2 quarters · filed 2025-02-28 | -$20.50M derived: sum of 3 quarters · filed 2025-02-28 | -$9.60M 10-K · filed 2025-02-28 | ||||
| 2022-10-01 | -$28.00M 10-Q · filed 2023-11-07 | -$43.90M 10-Q · filed 2022-11-08 | -$44.80M derived: sum of 2 quarters · filed 2023-11-07 | -$33.90M 10-Q · filed 2023-11-07 | -$79.50M 10-Q · filed 2022-11-08 | |||
| 2022-07-02 | -$16.80M 10-Q · filed 2023-08-08 | -$39.50M 10-Q · filed 2022-08-09 | -$5.90M 10-Q · filed 2023-08-08 | -$42.60M 10-Q · filed 2022-08-09 | ||||
| 2022-04-02 | $10.80M 10-Q · filed 2023-05-09 | |||||||
| 2021-10-02 | -$62.80M 10-Q · filed 2022-11-08 | -$186.40M derived: sum of 2 quarters · filed 2022-11-08 | -$277.10M 10-Q · filed 2022-11-08 | |||||
| 2021-07-03 | -$123.60M 10-Q · filed 2022-08-09 | -$213.80M 10-Q · filed 2022-08-09 | ||||||
| 2020-12-31 | -$257.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$228.80M derived: sum of 2 quarters · filed 2021-11-12 | -$211.20M derived: sum of 3 quarters · filed 2021-11-12 | -$148.60M 10-K · filed 2021-03-01 | ||||
| 2020-09-26 | $28.50M 10-Q · filed 2021-11-12 | -$154.50M 10-Q · filed 2020-11-05 | $46.10M derived: sum of 2 quarters · filed 2021-11-12 | $108.70M 10-Q · filed 2021-11-12 | $18.60M 10-Q · filed 2020-11-05 | $100.40M derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-06-27 | $17.60M 10-Q · filed 2021-08-11 | $63.80M 10-Q · filed 2020-08-05 | $80.20M 10-Q · filed 2021-08-11 | $173.10M 10-Q · filed 2020-08-05 | $71.90M derived: sum of 3 quarters · filed 2021-08-11 | $180.00M derived: sum of 4 quarters · filed 2021-08-11 | ||
| 2020-03-28 | $62.60M 10-Q · filed 2021-05-12 | $54.30M derived: sum of 2 quarters · filed 2021-05-12 | $162.40M derived: sum of 3 quarters · filed 2021-05-12 | $166.70M derived: sum of 4 quarters · filed 2021-05-12 | ||||
| 2019-12-31 | -$8.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $99.80M derived: sum of 2 quarters · filed 2021-03-01 | $104.10M derived: sum of 3 quarters · filed 2021-03-01 | $172.40M 10-K · filed 2021-03-01 | ||||
| 2019-09-28 | $108.10M 10-Q · filed 2020-11-05 | $112.40M derived: sum of 2 quarters · filed 2020-11-05 | $180.70M 10-Q · filed 2020-11-05 | |||||
| 2019-06-29 | $4.30M 10-Q · filed 2020-08-05 | $72.70M 10-Q · filed 2020-08-05 | ||||||
| 2018-12-31 | $96.80M 10-K · filed 2021-03-01 | |||||||
| 2016-12-31 | -$1.36B derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | -$2.95B derived: sum of 2 quarters · filed 2018-03-01 | -$3.48B derived: sum of 3 quarters · filed 2018-03-01 | -$4.01B 10-K · filed 2018-03-01 | ||||
| 2016-10-01 | -$1.59B 10-Q/A · filed 2017-05-23 | -$1.25B 10-Q · filed 2016-11-10 | -$2.12B derived: sum of 2 quarters · filed 2017-05-23 | -$2.65B 10-Q/A · filed 2017-05-23 | -$1.39B 10-Q · filed 2016-11-10 | -$2.86B derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2016-07-02 | -$534.30M 10-Q/A · filed 2017-05-22 | $194.30M 10-Q · filed 2016-08-10 | -$1.06B 10-Q/A · filed 2017-05-22 | -$138.80M 10-Q · filed 2016-08-10 | -$1.27B derived: sum of 3 quarters · filed 2018-03-01 | -$981.00M derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2016-04-02 | -$527.70M 10-Q/A · filed 2017-05-22 | -$333.10M 10-Q · filed 2016-05-16 | -$737.00M derived: sum of 2 quarters · filed 2018-03-01 | -$446.70M derived: sum of 3 quarters · filed 2018-03-01 | -$438.00M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-12-31 | -$209.30M derived: 10-K 6 month − 10-Q/A 3 month · filed 2018-03-01 | $81.00M 10-K · filed 2018-03-01 | $38.30M 10-KT · filed 2016-02-25 | $89.70M derived: sum of 3 quarters · filed 2018-03-01 | $87.00M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-09-26 | $290.30M 10-Q/A · filed 2017-05-23 | $142.00M 10-Q · filed 2016-11-10 | $299.00M derived: sum of 2 quarters · filed 2017-05-23 | $296.00M 10-Q/A · filed 2017-05-23 | $154.70M 10-Q · filed 2016-11-10 | |||
| 2015-06-27 | $8.70M 10-Q/A · filed 2017-05-22 | $87.30M 10-Q · filed 2016-08-10 | $6.00M 10-Q/A · filed 2017-05-22 | $11.90M 10-Q · filed 2016-08-10 | $250.20M 10-K · filed 2018-03-01 | $122.50M 10-K · filed 2015-08-13 | ||
| 2015-03-28 | -$2.70M 10-Q/A · filed 2017-05-22 | -$75.40M 10-Q · filed 2016-05-16 | ||||||
| 2014-06-28 | $104.50M derived: 10-KT 12 month − 10-K 9 month · filed 2016-02-25 | $374.60M 10-KT · filed 2016-02-25 | $212.80M 10-K · filed 2015-08-13 | |||||
| 2014-03-29 | $270.10M 10-K · filed 2014-08-14 | |||||||
| 2013-03-30 | -$616.30M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |